Search for: "CELGENE"
Results 81 - 100
of 181
Sorted by Relevance
|
Sort by Date
26 Sep 2015, 9:05 pm
Strafford will be offering a webinar/teleconference entitled "Hedge Fund IPR Challenges to Pharma Patents: Latest Developments and Strategies to Strengthen Patents -- Lessons From PTAB Denial of Acorda Therapeutics IPR, Celgene's Sanctions Motion, and More" on October 12, 2015 from 1:00 to 2:30 pm (EDT). [read post]
11 Oct 2015, 9:38 pm
October 12, 2015 - "Hedge Fund IPR Challenges to Pharma Patents: Latest Developments and Strategies to Strengthen Patents -- Lessons From PTAB Denial of Acorda Therapeutics IPR, Celgene's Sanctions Motion, and More" (Strafford) - 1:00 to 2:30 pm (EDT) October 13, 2015 - Post-Grant Practice Roundtable Discussion (George Washington Law School) - George Washington University Law School October 13, 2015 - Patent Quality Chat webinar series (U.S. [read post]
7 Jun 2012, 10:46 pm
The test will be used by Novartis, Sanofi SA, Johnson & Johnson and Celgene to analyze patients in early-stage clinical trials of new cancer drugs to identify patients most likely to benefit from the drug and to accelerate the drug approval process. [read post]
19 Feb 2014, 6:57 am
• Bristol-Myers Squibb Company • Celgene Corporation • GE Healthcare Inc. [read post]
17 Mar 2019, 7:48 pm
Court Rejects Alvogen’s Patent Challenge for Celgene’s Cancer Drug (Source: Yahoo Finance) Megan Rose Dickey: BlackBerry Sues Twitter for Patent Infringement (Source: Tech Crunch) Richard Borsuk, Christopher Cushing and Jonathan Oatis: Foxconn Rejects Microsoft Patent Lawsuit, Says Never Had to Pay Royalties (Source: Reuters) Brian Heater: Google Filed a Folding Phone Patent Application, Too (Source: Tech Crunch) Source: WIPO Commentary and Journal Articles: Atty.… [read post]
22 Jun 2020, 8:15 am
Petitions denied: Collabo (retroactive IPR violates due process & takings); Celgene (same); Enzo (Same) Hospira (limits on DOE); CJ CheilJedang (same) Comcast (mootness of ITC decision for expired patent) Federal Circuit decision Vacated & Remanded: Emerson Electric Co. [read post]
17 Feb 2009, 2:00 pm
Dinner--7:00 p.m.Honoring:Sol Barer, Phd, CEO Celgene for Leadership in Transformational Medicine --Rich Bagger, Senior VP for Worldwide Public Affairs & Policy, Pfizer, and former New Jersey State Senator--Co-Chairman--The honorable Mike Ferguson, Former Member, US House of Representatives--Co-Chairman--John Stossel, Host, 20/20--EmceeThis Event is Benefitting the Odysssey Initiative for Biomedical Innovation and Human Health of the Center for… [read post]
11 Jan 2022, 6:04 am
Celgene timely appealed. [read post]
28 Oct 2010, 10:14 am
Consider, for example, a recent quarterly report from Celgene Corporation, which states with respect to Risk Evaluation and Mitigation Strategies (“REMS”) that: In the fourth quarter of 2009, we received a civil inquiry and demand from the [Federal Trade Commission (“FTC”)]. [read post]
3 Apr 2011, 10:21 pm
” Celgene’s response to Dr. [read post]
18 Oct 2011, 10:47 am
Michio Kaku (physics professor and author), Jim Simons (mathematician and investment firm leader) and Bill Joy (former chief scientist at Sun Microsystems and now partner in a greentech practice), and Bob Hugin (CEO of Celgene). [read post]
12 May 2020, 9:07 am
Celgene Corp. v. [read post]
4 Jan 2016, 10:56 am
Revlimid represented 65% of Celgene's product sales in 2014. [read post]
30 Sep 2021, 8:50 am
Initially, Celgene and another pharmaceutical company, GlaxoSmithKline, were intrigued by the promise of Theranos’ devices. [read post]
28 Aug 2019, 12:28 pm
Cir. 2016). (...)In any event, even if Arthrex’s patent had issued priorto the passage of the AIA, our court recently rejected arguments similar to Arthrex’s in Celgene Corp. v. [read post]
6 Jun 2011, 11:51 am
Celgene has 461 million shares outstanding. [read post]
3 Jun 2015, 1:40 pm
In more detail, from the Celgene Corporation Prescribing information for Pomalyst (accessed 6/3/15): POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. [read post]
3 Aug 2017, 8:15 am
Take for example the $280 million that Celgene has agreed to pay to settle fraud claims over its marketing of Thalomid and Revlimid for unapproved uses. [read post]
4 Jun 2020, 2:58 am
Sony Corporation, No. 19-601; Celgene Corporation v. [read post]
14 Nov 2007, 8:59 pm
Teva Thalomid: Celgene v. [read post]
